198481-32-2

If you are looking for a supplier or manufacturer of Bazedoxifene (CAS No.: 198481-32-2) please contact us. We have more than 10 years of experience in custom synthesis of compounds. We can provide customers with custom synthesis from grams to kilograms and the production of tons of compounds. Now, we also hope to meet your needs for Bazedoxifene (CAS No.: 198481-32-2) and other compounds. We can provide high-quality compounds and good service for you.

Send Inquiry

Product Description

Name	Bazedoxifene
Synonyms	TSE-424; Conbriza; 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol
Molecular Formula	C₃₀H₃₄N₂O₃
Molecular Weight	470.60300
CAS Number	198481-32-2
purity	≥99%
Storage conditions	Sealed in dry,Store in freezer, under -20°C
Availability	On demand

Application: Bazedoxifene (CAS No.: 198481-32-2) is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. Bazedoxfiene is the result of an exclusive research collaboration between Wyeth Pharmaceuticals and Ligand Pharmaceuticals.
It is approved in the European Union (marketed in Italy and Spain) and Japan, and is in the late phases of review by the United States' Food and Drug Administration (FDA). When approved, bazedoxifene is to be sold by Pfizer under the tradename Viviant in the US, Japan and Conbriza in the EU. Bazedoxifene's combination with conjugated estrogens, Aprela, is undergoing Phase III studies for the treatment of postmenopausal symptoms (including the prevention of postmenopausal osteoporosis/treatment of osteopenia).
The drug is being investigated for possible use in dyspareunia (painful sexual intercourse).
It is also being studied for possible treatment of breast cancer and pancreatic cancer.

Hot Tags: